Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Codexis has widened its agreement with Teva Pharmaceutical Industries by completing its technology transfer of custom biocatalysts for manufacturing of three undisclosed pharmaceutical products to Teva.
Subscribe to our email newsletter
Among the three products, two products have been transferred for pilot manufacturing and the remaining one product for full scale commercial manufacturing.
Under the agreement, Teva will use Codexis biocatalysis technology for re-engineering key process steps for manufacturing covered generic products.
Codexis senior vice president and chief business officer Joseph Sarret said they are developing custom biocatalytic manufacturing processes for four Teva products, and the transfer to pilot and commercial manufacturing is important recognition of the cost savings and value-added technology that Codexis brings to the competitive generics marketplace.